ZR-CHOP in DLBCL With Specific Gene Abnormality
This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.
Diffuse Large B Cell Lymphoma
DRUG: zanubrutinib
3-year progression free survival, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Objective response rate, complete remission and partial remission, assessed up to 36 months|3-year event free survival, From date of enrollment until the date of an event, including progression, death from any cause, new treatment., assessed up to 36 months|3-year overall survival, From date of enrollment until the date of death from any cause, assessed up to 36 months
This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality, including MYC translocation, MYD88 mutation, CD79B mutation, NOTCH1 mutation and TP53 mutation. all patients received 6 cycle therapy.